Microbiology Paper-I — Model Answers

---

SECTION A — LONG ANSWER QUESTIONS (Attempt Any Two) [2 × 20 = 40 Marks]

---

Q1(a): Role of Microbes in Immune-mediated Disorders; Causation of Non-communicable Diseases; Influence of Commensal Microbiome on Health [20 Marks]

Introduction

---

Part I: Role of Microbes in Immune-mediated / Autoimmune Disorders

• Streptococcus pyogenes (Group A Strep) → M-protein mimics cardiac myosin → Rheumatic fever / rheumatic heart disease.
• Campylobacter jejuni GM1 ganglioside → Guillain-Barré syndrome.
• Klebsiella pneumoniae nitrogenase shares epitopes with HLA-B27 → Ankylosing spondylitis (Klebsiella – AS association).

---

Part II: Microbial Causation of Non-communicable Diseases

• Chlamydia pneumoniae and CMV found in atherosclerotic plaques; promote macrophage foam cell formation.
• Chronic H. pylori infection linked to coronary artery disease via CagA-mediated endothelial injury.
• Periodontal bacteria (Porphyromonas gingivalis) translocate and accelerate atherogenesis.

• Altered gut microbiome (dysbiosis) → increased Firmicutes : Bacteroidetes ratio → enhanced energy extraction → obesity.
• Adenovirus 36 (Ad-36): direct adipogenic effect; associated with human obesity.
• Gut dysbiosis → lipopolysaccharide (LPS) translocation → metabolic endotoxemia → insulin resistance → Type 2 Diabetes.

• Toxoplasma gondii latent infection → behavioral changes; associated with schizophrenia risk.
• Gut-brain axis: dysbiosis linked to depression, autism spectrum disorder via altered serotonin/GABA production.
• EBV reactivation as a trigger in multiple sclerosis (MS).

---

Part III: Influence of Commensal Microbiome on Health

• Promotes maturation of GALT (Gut-Associated Lymphoid Tissue): Peyer's patches, mesenteric lymph nodes.
• Bacteroides fragilis polysaccharide A (PSA) promotes Th1/Treg balance; prevents Th2-skewing and allergy.
• Germ-free animals have underdeveloped immune systems and hypersensitive Th2 responses (Hygiene Hypothesis).
• Short-chain fatty acids (SCFAs: butyrate, propionate, acetate) from fermentation → induce colonic Treg differentiation → mucosal tolerance.

• Fermentation of non-digestible fibers → SCFAs (energy for colonocytes; butyrate is primary fuel for colonocytes).
• Synthesis of Vitamin K₂ and B vitamins (B12, folate, biotin).
• Bile acid biotransformation: primary → secondary bile acids; regulates cholesterol metabolism.
• Tryptophan metabolism → serotonin (95% synthesized in gut) and indoles.

• Butyrate upregulates tight junction proteins (claudin, occludin) → maintains epithelial barrier.
• Dysbiosis → "leaky gut" → translocation of LPS → systemic inflammation.

• IBD (Crohn's disease, ulcerative colitis): reduced diversity, loss of Faecalibacterium prausnitzii
• C. difficile infection
• Obesity, Type 2 Diabetes
• Colorectal cancer
• Anxiety and depression

---

Q1(b): Bacteriophage Typing — Importance, Procedure, Reference Centers, Examples [20 Marks]

Introduction

---

Principle

---

Importance of Bacteriophage Typing

1. Epidemiological Surveillance: Identifies the source of an outbreak and tracks transmission chains.
2. Distinguishes strains within species: Useful where serotyping and biochemical methods cannot differentiate strains.
3. Nosocomial outbreak investigation: Phage typing was the gold standard for Staphylococcus aureus and Salmonella typhi outbreak investigation for decades.
4. Food microbiology: Typing of Salmonella, Listeria, E. coli O157:H7 in food-borne outbreaks.
5. Historical significance: Still valuable in low-resource settings; now complemented by molecular methods (MLST, WGS).

---

Bacteriophage Typing Sets (RTD — Routine Test Dilution)

---

Procedure: Phage Typing of Staphylococcus aureus

• International Set of 23 typing phages (RTD)
• Test strain (overnight culture on nutrient agar)
• Nutrient agar plates, broth
• Sterile loop, pipettes

• Inoculate test organism in nutrient broth; incubate 4 hours at 37°C (log-phase growth).
• Flood the surface of a nutrient agar plate (10 cm) with 0.5 mL of the broth culture; drain excess; allow surface to dry 10–15 minutes.

• Using a loop or Pasteur pipette, apply one drop (approximately 0.02 mL) of each phage (RTD) to a designated, pre-marked square on the agar lawn.
• Allow phage drops to dry; do NOT mix drops.

• Incubate at 37°C (some labs use 30°C for better results) for 16–18 hours.

• Examine plates for lysis (clear areas in bacterial lawn).
• Record: ++ (confluent lysis), + (semi-confluent), OL (opaque lysis), < 20 plaques, ≥ 20 plaques, inhibition.

• Strains with identical phage lysis patterns = same phage type = epidemiologically related.
• Strains not lysed by any phage = "untypeable" (UT).

---

Other Methods of Bacterial Typing

---

National and International Reference Centers

---

Q1(c): Water Quality Investigation — Waterborne Diseases, Microbiological Tests, Coliform Counts [20 Marks]

Clinical Scenario Recap

---

Part 1: Likely Waterborne Diseases Affecting the Community [2 Marks]

• Cholera (Vibrio cholerae): profuse rice-water diarrhoea
• Typhoid / Paratyphoid (Salmonella typhi / paratyphi): enteric fever
• Bacillary dysentery (Shigella spp.): bloody diarrhoea
• ETEC / EHEC (E. coli): traveller's diarrhoea, HUS
• Campylobacteriosis (Campylobacter jejuni): bloody diarrhoea
• Leptospirosis (Leptospira spp.): especially from flood water, animal contamination

• Hepatitis A / E (feco-oral route, river water)
• Rotavirus, Norovirus: acute watery diarrhoea

• Giardiasis (Giardia lamblia): chronic malabsorptive diarrhoea
• Amoebiasis (Entamoeba histolytica): amoebic dysentery
• Cryptosporidiosis (Cryptosporidium parvum): watery diarrhoea, chlorine-resistant

---

Part 2: Microbiological Tests for Disease-Causing Organisms in River Water [6 Marks]

A. Qualitative Methods

1. Direct Microscopy
   • Wet mount: motile protozoa (Giardia cysts, Cryptosporidium oocysts)
   • Acid-fast staining: Cryptosporidium oocysts (modified ZN stain)
   • Dark-field: Leptospira (thin spirochaetes)
2. Culture-Based Methods
   • Vibrio cholerae: Enrichment in APW (Alkaline Peptone Water, pH 8.6), then TCBS agar (yellow colonies)
   • E. coli / coliforms: MacConkey agar (lactose-fermenting pink colonies)
   • Salmonella / Shigella: SS agar, XLD agar
   • Campylobacter: CCDA (charcoal cefoperazone deoxycholate agar), microaerophilic at 42°C
   • Water filtration (membrane filtration): pass 100–500 mL through 0.45 μm membrane → place membrane on selective medium
3. Virological Methods
   • PCR / RT-PCR: Norovirus, Rotavirus, HAV from concentrated water samples
   • Cell culture: Enteroviruses
4. Molecular Methods
   • Multiplex PCR / metagenomics: detect all pathogens simultaneously
   • qPCR for quantification

B. Quantitative Methods

1. Most Probable Number (MPN) Method — for coliform counting
2. Membrane Filtration (MF) Method — direct colony count
3. Standard Plate Count (SPC / HPC) — total heterotrophic bacterial count; acceptable limit: <500 CFU/mL (drinking water)

---

Part 3: Presumptive Coliform Count and Differential (Fecal) Coliform Count [6 Marks]

Background: Indicator Organisms

• They are always present in large numbers in human and animal feces.
• They survive longer in water than most pathogens.
• They are easier and safer to detect than primary pathogens.
• Their absence = safety; their presence = risk of pathogen contamination.

---

Most Probable Number (MPN) Method

• Medium: Lactose broth (or MacConkey broth) with Durham's tube in test tubes.
• Procedure:
  1. Prepare 5 tubes each of 10 mL double-strength lactose broth + 10 mL water sample.
  2. 5 tubes each of 10 mL single-strength lactose broth + 1 mL water sample.
  3. 5 tubes each of 10 mL single-strength lactose broth + 0.1 mL water sample.
  4. Incubate at 37°C for 48 hours.
• Positive: Gas production in Durham's tube = presumptive positive for coliform.
• Count positive tubes at each dilution → refer MPN table → report as MPN/100 mL.

• From each presumptive positive tube → subculture onto Brilliant Green Bile Broth (BGBB) or Endo agar / EMB agar.
• Incubate at 37°C × 48 hours.
• Gas in BGBB = confirmed coliform.
• Green metallic sheen on EMB = E. coli.

• From confirmed positive → streak on Levine's EMB → identify colonies → Gram stain (Gram-negative rods) → confirm gas from lactose in broth.
• Tests the complete IMViC pattern (E. coli: ++-- pattern).

---

Differential Fecal Coliform Count (EC Test)

• Inoculate from each confirmed positive broth into EC broth (with Durham's tube).
• Incubate in water bath at 44.5°C for 24 hours (strict temperature control essential).
• Gas production = fecal coliform (thermotolerant coliform) positive.
• Transfer to tryptone broth → incubate 44.5°C → indole test.
• Indole positive = E. coli confirmed.

• Filter 100 mL water through 0.45 μm cellulose acetate membrane.
• Place membrane on m-Endo agar (total coliforms) or m-FC agar (fecal coliforms, incubated at 44.5°C).
• Count blue colonies on m-FC = fecal coliforms; express as CFU/100 mL.

---

WHO / BIS Drinking Water Standards

---

Part 4: Interpretation and Public Health Response [6 Marks]

Interpretation of Results

Immediate Interventions

1. Issue boil-water advisory immediately to the community (boiling at 100°C for 1 minute kills all pathogens including cysts).
2. Temporary distribution of safe bottled/tanker water.
3. Chlorination of the water source: Free residual chlorine of 0.2–0.5 mg/L after 30-minute contact time (effective for bacteria and viruses, not Cryptosporidium).
4. Case identification and treatment: ORS for diarrheal illness; antibiotics (ciprofloxacin for cholera, typhoid) per sensitivity.
5. Environmental sampling to identify exact contamination source (upstream survey, latrine proximity mapping).
6. Community mobilization: hand hygiene promotion, open defecation-free campaigns.

Long-term Interventions

1. Water treatment plant: installation of filtration (coagulation-flocculation-sedimentation) + chlorination + UV.
2. Sanitation infrastructure: construction of toilets, sewage treatment; prevent river contamination.
3. Regular water quality surveillance: monthly MPN/MF testing; annual physicochemical analysis.
4. Health education: WASH (Water, Sanitation, Hygiene) training.
5. Vector/animal control: reduce animal defecation near water sources.
6. Strengthening IDSP (Integrated Disease Surveillance Programme) for early outbreak detection.

---

SECTION B — SHORT QUESTIONS (Attempt Any Six) [6 × 10 = 60 Marks]

---

Q2(a): Unique Features of Mycoplasma; Pathogenesis and Diagnosis of Atypical Pneumonia [10 Marks]

Unique Features of Mycoplasma

1. No cell wall: Lacks peptidoglycan cell wall (the defining feature). Therefore:
   • Gram staining does NOT work (cannot be stained by conventional Gram stain)
   • Resistant to β-lactam antibiotics (penicillins, cephalosporins) which target cell wall synthesis
   • Pleomorphic: spheres, rings, filaments (no rigid shape)
2. Contains sterols in cell membrane: Unlike all other bacteria, the cell membrane contains cholesterol (obtained from host or culture media); this stabilizes the membrane in the absence of a cell wall.
3. Smallest genome: ~580 kb in M. genitalium (smallest of any self-replicating organism); only ~500 genes.
4. Obligate parasites: Cannot synthesize cholesterol, purines, or amino acids; requires rich media or host.
5. Filterable through 0.45 μm membrane: Pass through bacteriological filters designed to remove bacteria.
6. Culture: Requires special media containing serum, cholesterol, and yeast extract. Classical medium: Hayflick's medium (beef heart infusion, horse serum, yeast extract). Colonies appear as "fried egg" appearance (dense center, peripheral flat zone) on agar.
7. UGA codon: In most organisms UGA = stop codon; in Mycoplasma it codes for tryptophan (variant genetic code).
8. Gliding motility: M. pneumoniae has a tip organelle (P1 adhesin tip) that allows attachment and gliding along epithelial surfaces.

---

Mycoplasma pneumoniae — Pathogenesis of Atypical Pneumonia

• Most common cause of primary atypical pneumonia ("walking pneumonia").
• Epidemics every 4–7 years; endemic otherwise.
• Peak incidence: school-age children and young adults.
• Transmission: respiratory droplets; close contact settings (schools, barracks, families).

1. Attachment: P1 adhesin tip attaches to sialoglycoproteins on the respiratory epithelium surface.
2. Cytotoxicity: Produces hydrogen peroxide (H₂O₂) and superoxide radicals → oxidative damage to cilia → ciliastasis → loss of mucociliary clearance.
3. CARDS toxin (Community-Acquired Respiratory Distress Syndrome toxin): ADP-ribosyltransferase activity; causes vacuolation and ciliostasis.
4. Immune-mediated damage:
   • TLR2 activation → inflammatory cytokines (IL-8, TNF-α).
   • Autoimmune: Cold agglutinins (IgM anti-I antigen on red blood cells) produced → haemolytic anaemia; induced by polyclonal B-cell activation (molecular mimicry with I-antigen on M. pneumoniae glycolipid).
5. Extrapulmonary spread: Bacteremia occurs rarely; extrapulmonary manifestations via direct invasion and immune mechanisms.

• Gradual onset (2–3 week incubation)
• Persistent dry, hacking cough (hallmark)
• Low-grade fever, headache, malaise
• Minimal physical findings on chest exam despite abnormal X-ray (patchy bilateral infiltrates)
• "Walking pneumonia" — patient ambulates despite pneumonia
• Extrapulmonary: haemolytic anaemia (cold agglutinins), erythema multiforme, Stevens-Johnson syndrome, encephalitis, myocarditis, pericarditis, arthritis, bullous myringitis (pathognomonic but rare)

---

Diagnosis

• Macrolides: Azithromycin (drug of choice; especially children)
• Tetracyclines: Doxycycline (adults)
• Fluoroquinolones: Levofloxacin (second line)
• NOT penicillins or cephalosporins (no cell wall).

---

Q2(b): Zoonotic Diseases; Bacterial Zoonoses; Pathogenesis and Diagnosis — Brucellosis [10 Marks]

Definition

• Anthropozoonosis: primary reservoir in animals; transmitted to humans (Brucellosis, rabies).
• Zooanthroponosis: primary reservoir in humans; transmitted to animals (human TB to cattle).
• Amphixenosis: maintained in both (Staphylococcal infections).

---

Bacterial Zoonotic Diseases

---

Specific Example: Brucellosis

Pathogenesis

1. Entry: Via GI tract (ingestion of raw milk), skin abrasion, mucous membranes, or respiratory tract (inhalation of aerosols in abattoirs).
2. Phagocytosis without killing: Brucella resists neutrophil killing because:
   • Smooth LPS (S-LPS) inhibits complement activation and opsonization.
   • VirB type IV secretion system (T4SS): injects effector proteins that remodel the intracellular environment.
   • Resists reactive oxygen species and acidification of phagosomes.
   • Inhibits phagosome-lysosome fusion.
3. Lymphatic spread: From initial macrophages → regional lymph nodes → bacteremia (brucellemia).
4. Intracellular persistence: Survives within macrophages, monocytes; establishes "Brucella-containing vacuoles (BCV)" in endoplasmic reticulum → chronic infection.
5. Granuloma formation: CD4+ T-cell mediated type IV hypersensitivity → granulomas in spleen, liver, bone marrow, lymph nodes.
6. Erythritol: Present in bovine placenta; Brucella preferentially metabolizes erythritol → explains tropism for gravid uterus in animals → abortion; erythritol absent in human placenta (explains why abortion is uncommon in human brucellosis).

• Undulant fever (fever pattern: rises in evening, returns to normal by morning; weeks–months pattern)
• Profuse night sweats with characteristic musty odor ("wet hay" odor)
• Arthralgia, myalgia, fatigue
• Hepatosplenomegaly, lymphadenopathy
• Epididymo-orchitis in males (unilateral, most common focal complication)
• Neurobrucellosis, endocarditis (rare but serious)

Diagnosis of Brucellosis

• Blood culture (in Castañeda bottle): 85–90% sensitive in acute phase; requires 4–6 weeks; BSL-3 precautions required (laboratory hazard).
• Bone marrow culture: more sensitive (90–95%) even in chronic phase.

• Highly sensitive (>90%) and specific; detects Brucella DNA in blood, bone marrow, CSF.
• Useful for chronic and partially treated cases.
• Real-time PCR: quantitative; monitors treatment response.

---

Q2(c): Syndemic of TB and AIDS; NTEP and AIDS Control Programs; Recent Screening and Early Diagnosis [10 Marks]

Syndemic Concept

---

TB-HIV Biological Interaction

1. CD4+ T-cell depletion: TB requires CD4+ TH1 cells for granuloma formation and control of M. tuberculosis. HIV destroys CD4+ cells → failure to contain Mtb.
2. Macrophage dysfunction: HIV impairs macrophage killing of intracellular Mtb.
3. Reactivation: Latent TB infection (LTBI) reactivates at 5–15% per year in HIV+ (versus 5–10% per lifetime in HIV-).
4. Atypical presentation: HIV-TB presents with more extrapulmonary TB, smear-negative TB, and disseminated TB; diagnosis is harder.
5. Immune reconstitution inflammatory syndrome (IRIS): After ART initiation, paradoxical worsening of TB as immunity recovers.

1. Immune activation: Mtb infection → TNF-α, IL-6 upregulation → increased HIV replication.
2. Accelerates HIV progression: TB in HIV+ accelerates CD4 decline; doubles risk of AIDS progression and death.
3. Increased CCR5/CXCR4 expression: TB-driven immune activation upregulates HIV co-receptors on CD4 cells.

• ~10.6 million TB cases globally (WHO 2022); India has the highest TB burden (~28% global).
• 6.7% of TB patients globally are HIV co-infected; in sub-Saharan Africa: up to 60%.
• TB is the leading cause of death in HIV-positive patients.

---

NTEP (National TB Elimination Programme)

• Goal: TB Elimination by 2025 (ahead of SDG 2030 goal).
• NSP (National Strategic Plan) 2017–2025: "FIND, TREAT, PREVENT, BUILD."
• NIKSHAY Portal: Digital TB notification and treatment monitoring platform.
• NIKSHAY Poshan Yojana: ₹500/month nutritional support to TB patients.
• TB-HIV Integration: All TB patients tested for HIV; all HIV patients screened for TB.

• Every diagnosed TB patient → Provider Initiated Testing and Counselling (PITC) for HIV.
• HIV-positive TB patients → enrolled in ART and given ART from the nearest ART centre.
• Isoniazid Preventive Therapy (IPT) / Tuberculosis Preventive Therapy (TPT): 6 months isoniazid (or 3 months weekly isoniazid + rifapentine = 3HP) for HIV+ contacts of TB.
• Cotrimoxazole preventive therapy (CPT): All HIV-TB patients receive cotrimoxazole prophylaxis.

• Managed by NACO (National AIDS Control Organisation).
• ART Programme: Free lifelong ART to all HIV+ patients (regardless of CD4 count — TasP: Treatment as Prevention).
• ICTC (Integrated Counselling and Testing Centres): HIV testing including TB patients.
• ART Centres: 700+ functional in India.
• Link Worker Scheme / ASHA: Community mobilization for testing.
• PMTCT: Prevention of mother-to-child transmission.

---

Recent Approaches: Screening and Early Diagnosis

• Every confirmed TB case → culture + DST for isoniazid, rifampicin, fluoroquinolones, second-line injectables.
• GeneXpert MTB/RIF (Xpert) detects Mtb + rifampicin resistance in ~2 hours (endorsed by WHO 2010–present).

• CBNAAT (Cartridge Based Nucleic Acid Amplification Test) = GeneXpert: placed in every district.
• TrueNat MTB+: POC platform (ICMR-developed); battery operated; suitable for primary health centres.
• LPA (Line Probe Assay): First-line (FL-LPA): detects INH and RIF resistance; Second-line (SL-LPA): detects FQ and SLI resistance.
• WGS: Comprehensive drug resistance profiling; emerging.

• Fourth-generation HIV tests (p24 antigen + antibody combo): reduce window period to 18 days.
• HIV self-testing kits (approved by CDSCO): enables community-level early detection.
• Index testing: Partners and children of HIV-positive individuals tested.

• Systematic screening of high-risk populations (household contacts, HIV+, prisoners, diabetics).
• Mobile X-ray vans + AI-assisted chest radiograph reading (CAD4TB, qXR) for mass TB screening.

• Urine LAM (Lipoarabinomannan) test: Alere Determine TB LAM Ag; for HIV+ with CD4 <200 cells/μL; detects Mtb LAM antigen in urine; enables diagnosis of disseminated TB at bedside.
• IGRA (Interferon Gamma Release Assays) — QuantiFERON-TB Gold Plus, T-SPOT.TB: detect LTBI; preferred over TST in HIV+ (not affected by BCG vaccination).

---

Q2(d): Role of H. pylori in Peptic Ulcer Disease; Methods for Diagnosis [10 Marks]

Role of H. pylori in Peptic Ulcer Disease

• Found in ~90–95% of duodenal ulcers and 70–85% of gastric ulcers.
• Present in 50% of world population (higher in developing countries, ~80%).

Virulence Factors

Mechanisms of Ulcer Formation

1. Disruption of mucosal defence: NH₃ (from urease), VacA, and lipase digest the protective mucus layer → epithelial exposure to acid.
2. Increased acid secretion: CagA-positive strains → stimulate antral G-cells to release gastrin → increased parietal cell acid secretion; also impairs D-cell somatostatin release.
3. Direct epithelial damage: VacA-induced apoptosis; CagA-mediated disruption of tight junctions.
4. Chronic gastritis: Neutrophilic and mononuclear infiltration (chronic active gastritis); progresses to gastric atrophy, intestinal metaplasia → cancer risk.
5. Duodenal ulcer mechanism: H. pylori in antrum → gastrin elevation → increased acid → bicarbonate secretion of duodenum overwhelmed → gastric metaplasia in duodenum → H. pylori colonizes duodenum → duodenal ulcer.

---

Diagnosis of H. pylori Infection

Non-Invasive Tests

Invasive Tests (Require Endoscopy + Biopsy)

• Triple therapy: PPI + Clarithromycin + Amoxicillin × 14 days (first-line where clarithromycin resistance <15%)
• Bismuth quadruple: PPI + Bismuth + Metronidazole + Tetracycline × 10–14 days
• Concomitant / Sequential therapy: Used where resistance is high.

---

Q2(e): Legionnaires' Disease [10 Marks]

Introduction

Legionella pneumophila — Characteristics

• Morphology: Gram-negative (stains poorly), thin rod (2–20 μm); flagellated; aerobic.
• Growth requirements: Fastidious; requires L-cysteine and iron for growth.
• Culture medium: BCYE agar (Buffered Charcoal Yeast Extract agar) supplemented with L-cysteine and ferric pyrophosphate; 35°C; 5% CO₂; 3–5 days.
• Does NOT grow on standard bacteriological media (blood agar, MacConkey agar).
• Gram stain: poorly stained by Gram stain; visualized by Dieterle's silver stain or direct fluorescent antibody (DFA) staining in tissues.

Epidemiology

• First identified after outbreak at American Legion convention in Philadelphia, 1976 (hence the name).
• Environmental niche: warm water (25–45°C) in cooling towers, hot water systems, whirlpool spas, hospital potable water.
• Two forms:
  • Legionnaires' disease: Pneumonia (lobar or multilobar); incubation 2–10 days.
  • Pontiac fever: Mild, self-limiting flu-like illness without pneumonia; incubation 24–48 hours; no fatalities.

Transmission

Pathogenesis

1. Legionella aerosols inhaled → reach alveoli → phagocytosed by alveolar macrophages.
2. Evades phagolysosomal fusion: uses Dot/Icm type IV secretion system → remodels phagosome into Legionella-containing vacuole (LCV) → recruits ER-derived vesicles.
3. Intracellular replication within macrophages (obligate intracellular within macrophages).
4. Cell lysis → spread → recruits neutrophils → inflammatory response → multilobar pneumonia.

Clinical Features

• Prodrome: high fever (>39°C), myalgia, malaise, headache.
• Dry then productive cough, pleuritic chest pain, dyspnoea.
• Classical triad: Pneumonia + Hyponatremia + Diarrhoea (GI symptoms in 50%).
• Relative bradycardia (pulse–temperature dissociation).
• Neurological: confusion, delirium (50%) — more than other CAP causes.
• Lab: hyponatremia (<130 mEq/L), elevated transaminases, raised LDH, haematuria.

Diagnosis

Treatment

• Fluoroquinolones: Levofloxacin, Moxifloxacin (drug of choice for severe disease)
• Macrolides: Azithromycin (first-line for milder cases, immunocompromised)
• Duration: 5–10 days (mild) to 21 days (immunocompromised).
• Beta-lactams and aminoglycosides: ineffective (intracellular organism).

Prevention

• Regular decontamination and disinfection of hospital water systems, cooling towers.
• Superheating water (>60°C) or hyperchlorination.
• Risk assessment under UK L8 ACOP / WHO guidelines.

---

Q2(f): Laboratory Diagnosis of Lyme Disease [10 Marks]

Introduction

Causative Agent

• Borrelia burgdorferi sensu lato (s.l.) complex.
• Gram-negative spirochaete; 20–30 μm long, tightly coiled; microaerophilic.
• Very fastidious; Barbour-Stoenner-Kelly (BSK) medium required; grows slowly (weeks).

Clinical Stages

---

Laboratory Diagnosis

Principle: Two-Tier Serological Testing (CDC/IDSA Recommended)

• Whole-cell sonicate or recombinant antigen Borrelia ELISA.
• Detects IgM (early: OspC, p39, p41 flagellin) and IgG (late: p18, p23, p28, p30, p39, p41, p45, p58, p66, p93).
• If negative in early disease when EM rash present: clinical diagnosis; treat without further testing.
• If positive or equivocal → proceed to Tier 2.

• Separates Borrelia proteins by molecular weight.
• IgM Western Blot (positive if ≥2 of 3 bands: p23, p39, p41): use only within first 4 weeks.
• IgG Western Blot (positive if ≥5 of 10 bands: p18, p23, p28, p30, p39, p41, p45, p58, p66, p93): use after 4 weeks of illness.
• Modified two-tier testing (MTTT): Both tiers use ELISA (second ELISA with different antigen set VlsE/C6); non-inferior to classic two-tier; endorsed by CDC 2019.

Other Diagnostic Methods

Interpretation Pitfalls

• Seronegative early disease: IgM antibodies take 2–4 weeks to develop; early disease (first 2 weeks with EM) is a clinical diagnosis — treat without waiting for serology.
• False positives: Cross-reactions with Treponema pallidum, EBV, CMV, autoimmune diseases (SLE, RA); Western blot confirms.
• Serofast state: IgG antibodies persist for years after successful treatment; positive test does not indicate active disease in previously treated patient.
• ELISA alone is insufficient — must be confirmed with Western blot (two-tier).

• Early localized: Doxycycline 100 mg BD × 14–21 days (or Amoxicillin, Cefuroxime)
• Neuroborreliosis / Carditis / Arthritis: Intravenous Ceftriaxone × 14–28 days

---

Q2(g): Audit of Antibiotic Prescribing Practice in a Tertiary Care Hospital [10 Marks]

Introduction

---

Objectives of the Audit

1. Measure the proportion of patients receiving antibiotics.
2. Assess appropriateness of antibiotic choice (type, dose, route, duration).
3. Evaluate compliance with hospital formulary and national/WHO treatment guidelines.
4. Identify trends in antibiotic consumption over time.
5. Generate data for intervention (education, policy change, formulary restriction).
6. Monitor for emergence of MDR organisms.

---

Types of Audit

• On a single pre-defined day, collect data on all inpatients receiving antibiotics.
• Classify as: therapeutic (community-acquired, hospital-acquired), surgical prophylaxis, or medical prophylaxis.
• Tools: WHO Global PPS, European Surveillance of Antimicrobial Consumption (ESAC-Net).

• Retrospective review of case records/prescriptions over a defined period.
• Assess: indication documented?, culture sent before antibiotic started?, de-escalation performed?, duration appropriate?

• Clinical outcomes (mortality, length of stay, re-infection) correlated with antibiotic prescribing patterns.

---

Audit Process (Steps)

• Hospital antibiotic policy / formulary.
• National Treatment Guidelines (e.g., AMR National Action Plan, ICMR guidelines).
• International guidelines: IDSA, WHO AWaRe classification.

• Identify all antibiotic prescriptions during audit period.
• For each prescription document:
  • Patient demographics (age, ward, diagnosis)
  • Antibiotic name, dose, route, frequency, duration
  • Indication (empirical/definitive/prophylactic)
  • Whether culture and sensitivity (C&S) done before starting
  • WHO AWaRe category: Access, Watch, Reserve
  • Whether antibiotic choice matches sensitivity report (if available)

• Calculate: DDD (Defined Daily Doses) per 100 bed-days (WHO standard metric for antibiotic consumption).
• DDDs/100 bed-days = (Total amount of antibiotic used × 100) / (DDD per WHO × patient-bed-days).
• Proportion of prescriptions with documentation of indication.
• Proportion appropriate vs. inappropriate.
• Proportion of "Watch" and "Reserve" antibiotics used.
• De-escalation rate (% of empirical therapy changed to narrower agent after culture).
• Surgical antibiotic prophylaxis: appropriate timing (within 60 min pre-incision) and duration (single dose for most surgeries).

• Present results to clinical departments, infection control committee, hospital administration.
• Compare with baseline or previous audit cycle.
• Identify outlier departments and wards.

• Educational sessions for prescribers.
• Implementation of order sets, clinical pathways.
• Formulary restrictions on Reserve antibiotics (e.g., colistin, carbapenems require Infectious Disease specialist approval).
• IV-to-oral switch protocol.
• Automatic stop orders for surgical prophylaxis.

• Re-audit after 3–6 months to assess impact of interventions (audit cycle / PDCA cycle).

---

Key Indicators Measured

---

WHO AWaRe Classification

• Access: First- and second-line antibiotics for common infections (e.g., amoxicillin, doxycycline, metronidazole).
• Watch: Higher resistance potential; require close monitoring (e.g., fluoroquinolones, 3rd-generation cephalosporins, carbapenems).
• Reserve: Last-resort antibiotics; strict indications only (e.g., colistin, linezolid, ceftazidime-avibactam).

---

Q2(h): Bacterial Meningitis in a 6-Year-Old — Clinical Diagnosis, Lab Diagnosis, Likely Organisms [10 Marks]

Clinical Scenario

Probable Clinical Diagnosis

• Neck stiffness (Kernig's and Brudzinski's signs): meningeal irritation.
• Photophobia: meningeal irritation, photosensitivity of inflamed meninges.
• High-grade fever: systemic inflammation.
• CSF findings confirm bacterial meningitis:
  • ↑ Protein (>45 mg/dL, typically 100–500 mg/dL in bacterial)
  • ↓ Glucose (CSF:serum glucose ratio <0.4)
  • Neutrophilic pleocytosis (hundreds to thousands of cells/mm³, >80% PMNs)

• Viral (aseptic) meningitis: lymphocytic pleocytosis, normal glucose
• Tuberculous meningitis: lymphocytic pleocytosis, very low glucose, high protein; chronic
• Fungal meningitis (Cryptococcal): lymphocytic, India ink positive; in immunocompromised

---

Most Likely Causative Organisms (by Age Group)

---

Laboratory Diagnosis of Bacterial Meningitis

Step 1 — Lumbar Puncture and CSF Analysis

• Turbid/cloudy/purulent: bacterial meningitis
• Clear: viral / early bacterial

Step 2 — Direct Microscopy (Gram Stain — First Priority)

• Gram stain of CSF centrifuged deposit:
  • S. pneumoniae: Gram-positive diplococci (lancet-shaped)
  • N. meningitidis: Gram-negative diplococci (kidney-bean shaped, intracellular in PMNs)
  • H. influenzae: Gram-negative coccobacilli
  • Listeria: Gram-positive rods
• Sensitivity: 60–90% in untreated bacterial meningitis; decreases after antibiotic therapy.

Step 3 — Culture (Gold Standard)

• Blood culture (paired with CSF): positive in ~80% of untreated bacterial meningitis.
• CSF culture: inoculate directly onto:
  • Blood agar (all organisms)
  • Chocolate agar (enriched; N. meningitidis, H. influenzae)
  • MacConkey agar (Gram-negative rods)
  • Thioglycollate broth (anaerobes, slow growers)
• Incubate 35–37°C in 5–10% CO₂ (capnophilic for N. meningitidis).
• Subculture from broth at 48 and 72 hours; keep for 7 days.
• Organism identification: colonial morphology, biochemical tests, automated systems (VITEK 2).
• Antibiotic sensitivity testing (AST): MIC by broth microdilution or disc diffusion.

Step 4 — Rapid Antigen Detection

• Latex Agglutination Test (LAT): Detects polysaccharide capsular antigens of S. pneumoniae, N. meningitidis (A, B, C, Y, W135), H. influenzae type b, E. coli K1, GBS.
• Sensitivity: 50–100% depending on organism.
• Useful when cultures negative (partially treated meningitis).
• BinaxNOW: Rapid immunochromatographic test for S. pneumoniae antigen in CSF (highly sensitive and specific).

Step 5 — Molecular Methods

• PCR (Multiplex): Detects N. meningitidis, S. pneumoniae, H. influenzae, Listeria DNA simultaneously from CSF in 4–6 hours.
• FilmArray Meningitis/Encephalitis Panel: detects 14 organisms (bacteria, viruses, fungi) from CSF simultaneously in ~1 hour; especially valuable when cultures are negative.
• High sensitivity post-antibiotics: PCR remains positive even after 12–24 hours of antibiotic treatment.

Step 6 — Additional Tests

• Serum procalcitonin: >0.5 ng/mL favors bacterial over viral meningitis; >2 ng/mL strongly bacterial.
• Serum CRP: >20 mg/L suggests bacterial.
• Blood culture ×2 before antibiotic therapy.
• Coagulation profile: DIC screening (common complication of meningococcal meningitis).

---

Management Considerations

• Empirical antibiotic therapy should NOT be delayed for diagnostic workup in a sick child.
• For age 1 month – 18 years: Ceftriaxone (or cefotaxime) IV × 7–10 days.
• Add Dexamethasone (0.15 mg/kg QID × 4 days) if started before or with first dose of antibiotics → reduces hearing loss (especially for H. influenzae) and neurological complications.
• Chemoprophylaxis: Rifampicin for close contacts of N. meningitidis (alternative: ciprofloxacin single dose, ceftriaxone IM).
• Prevention: MenACWY vaccine, PCV13/PCV15 vaccine, Hib vaccine.

---

---

Paper Summary